Thursday, September 08, 2005

the SONT saga continues

Still waiting on Sontra Medical management to update shareholders (per their quarterly CC) about the status of two SONT-involved vaccine studies and also regarding the $3 million Bayer milestone payment due for their glucose monitor development project. Both of these events should be announced by the end of Q3 (ends Sept.) Nothing like waiting for the last minute.

One positive on SONT is that a director has recently been buying a decent amount of stock. Stay tuned.


Post a Comment

<< Home